

PRESS RELEASE

Ipca Laboratories Q3 FY15 Financial Results

Mumbai, February 7, 2015: Ipca Laboratories Limited today announced its unaudited standalone financial results for the third quarter ended 31st December, 2014.

Key Highlights of Q3 FY15

- Net Total Income down 11% at Rs. 747.09 crores.
- Domestic formulations income up 13% at Rs. 278.67 crores.
- Exports Income down 22% at Rs. 418.45 crores.
- EBITDA margin @ 16.36 %.
- Net Profit at Rs. 41.53 crores down 70%.

Q3 FY15 at a glance			(Rs. Crores)
Particulars	Q3 FY15	Q3 FY14	Growth
Net Total Income	747.09	838.37	-11%
Export Income	418.45	533.77	-22%
EBITDA	121.14	217.34	-44%
EBITDA Margin	16.36%	26.09%	-
Profit before Forex (gain) / loss and tax	79.70	191.74	-58%
Forex (gain) / loss	11.15	2.42	-
Net Profit after Forex (gain) / loss and tax	41.53	139.12	-70%
Earnings per share of Rs. 2/- each (Rs.)	3.29	11.02	-70%



Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613


E: ipca@ipca.com CIN: L24239MH1949PLC007837

Q3 FY15 Revenue break-up			(Rs. Crores)
Particulars	Q3 FY15	Q3 FY14	Growth
Formulations			
Domestic	278.67	246.33	13%
Exports	305.09	388.64	-21%
Total Formulations	583.76	634.97	-8%
APIs			
Domestic	37.01	41.89	-12%
Exports	113.36	145.13	-22%
Total APIs	150.37	187.02	-20%
Grand Total	734.13	821.99	-11 %

Key Highlights of 9 months FY15

- Net Total Income down 1% at Rs. 2478.65 crores.
- Domestic formulations income up 16% at Rs. 899.77 crores.
- Exports Income down 11% at Rs. 1391.76 crores.
- EBIDTA margin @ 19.81%.
- Net Profit at Rs. 248.32 crores down 27%.

9 months FY15 at a glance			(Rs. Crores)
Particulars	9 months FY15	9 months FY14	Growth
Net Total Income	2478.65	2500.41	-1%
Export Income	1391.76	1555.36	-11%
EBITDA	486.83	622.89	-22%
EBITDA Margin	19.81%	25.06%	-
Profit before Forex (gain) / loss and tax	371.41	544.88	-32%
Forex (gain) / loss	18.25	90.29	-
Net Profit after Forex (gain) / loss and tax	248.32	340.34	-27%
Earnings per share of Rs. 2/- each (Rs.)	19.68	26.97	-27%



Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005


Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837

9 months FY15 Revenue break-up (Crores)			(Rs.)
Particulars	9 months FY15	9 months FY14	Growth
Formulations			
Domestic	899.77	772.86	16%
Exports	999.04	1088.67	-8%
Total Formulations	1898.81	1861.53	2%
APIs			
Domestic	145.67	128.01	14%
Exports	392.72	466.69	-16%
Total APIs	538.39	594.70	-9%
Grand Total	2437.20	2456.23	-1%

About Ipca Laboratories:

Ipca is a fast growing pharmaceutical company with a strong thrust on exports which now account for 56% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients



Premchand Godha
Chairman & Managing Director



Encl: Unaudited Standalone Financial Results

Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22-62106050

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS NO. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444 F: +91 22 2868 6613

E: ipca@ipca.com CIN: L24239MH1949PLC007837